NA-931chemical structure NA-931, also known as Bioglutide™, is emerging as a significant advancement in the treatment of obesity. This novel peptide represents a first-in-class, oral, once-daily quadruple receptor agonist designed to activate multiple metabolic hormone receptors simultaneously. Unlike many existing injectable therapies, NA-931 offers the convenience of oral administration, positioning it as a promising solution for individuals seeking effective weight management with potentially fewer adverse events. Its mechanism of action targets key pathways involved in metabolism, appetite regulation, and energy expenditure, aiming to provide a comprehensive approach to tackling obesity.
At its core, NA-931 functions as a quadruple agonist, meaning it simultaneously activates four critical metabolic hormone receptors: insulin-like growth factor-1 (IGF-1), glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. This multi-receptor activation is central to its therapeutic potentialNA-931 (Bioglutide™) is the first in class, a quadruple .... By targeting these pathways, NA-931 aims to:
* Enhance insulin secretion: This helps in better glucose regulation, which is crucial for individuals with metabolic dysfunction.
* Suppress appetite: GLP-1 and GIP are known for their roles in signaling satiety, leading to reduced food intakeNA-931 - Drug Targets, Indications, Patents - Synapse.
* Increase energy expenditure: Glucagon and IGF-1 can influence metabolic rate, contributing to calorie burning.
* Regulate fuel metabolism and body composition: The inclusion of IGF-1 targets fuel metabolism and aims to preserve muscle mass while promoting fat loss2024年5月5日—By including IGF-1,NA-931 aims to regulate fuel metabolism and body composition, preserving muscle mass while promoting weight loss. The ....
This multifaceted approach distinguishes NA-931 from therapies that target only one or two of these receptors, offering a potentially more robust and holistic strategy for weight management.
NA-931 is currently undergoing various phases of clinical trials, with a significant focus on Phase 2 studies evaluating its safety and efficacy in adults with obesity or overweight. Early results from these trials have been encouraging. For instance, some studies have reported a 13.8% weight loss in 13 weeks with minimal side effects. Furthermore, a key finding highlighted in research is the potential for NA-931 to preserve muscle mass while facilitating weight loss, a critical factor often overlooked in weight management interventions.Biomed Industries' NA-931 Demonstrates Promising Phase I ...
The peptide is being investigated for its ability to achieve clinically meaningful weight loss. Its oral administration, once daily, adds to its appeal as a convenient treatment optionSAT-713 Phase 2 Clinical Trials Of Na-931 To Study Subjects Who Are .... Research is also exploring its potential synergistic effects when used in conjunction with other obesity medications, such as Tirzepatide, aiming to enhance efficacy and potentially mitigate adverse events2025年6月20日—NA-931 is a quadruple agonist of the insulin-like growth hormone- (IGF-1), glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) ....
The landscape of obesity treatment has been revolutionized by the advent of GLP-1 receptor agonistsSafety and Efficacy of NA-931 and Tirzepatide in Adults .... However, NA-931, also referred to as Bioglutide™, stands out due to its oral formulation and its status as a quadruple agonist. Unlike injectable medications like Ozempic or Mounjaro, which primarily target GLP-1 and sometimes GIP receptors, NA-931's simultaneous activation of IGF-1 and glucagon receptors offers a broader spectrum of metabolic influence.
This comprehensive targeting may lead to distinct benefits, including improved body composition and potentially a different side effect profile compared to single or dual-receptor agonists. The development of NA-931 signifies a move towards more sophisticated, multi-target therapies for metabolic diseases, aiming to address the complex biological underpinnings of obesity.Biomed Industries presents Phase 2 results for NA-931, a ...
As NA-931 progresses through clinical development, it holds considerable promise for transforming obesity treatment. Its oral delivery makes it more accessible and user-friendly for a wider patient population. The ongoing research aims to solidify its efficacy, safety profile, and optimal dosing strategies.2024年5月5日—By including IGF-1,NA-931 aims to regulate fuel metabolism and body composition, preserving muscle mass while promoting weight loss. The ...
For individuals considering NA-931, understanding its mechanism as a quadruple agonist and its potential benefits, such as muscle preservation alongside weight loss, is crucial. While early results are positive, further data from ongoing Phase 2 and future Phase 3 trials will be essential to fully establish its place in the therapeutic armamentarium against obesity and related metabolic dysfunctions. The development of Bioglutide™ represents a significant step forward in the quest for effective and convenient obesity management solutions.
Join the newsletter to receive news, updates, new products and freebies in your inbox.